Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia

References

• Silvennoinen O, Witthuhn BA, Quelle FW, Cleveland JL, Yi T, Ihle JN. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci U S A. 1993;90(18):8429–33. doi:10.1073/pnas.90.18.8429.
   PubMedGoogle Scholar
• Bagley CJ, Woodcock JM, Stomski FC, Lopez AF. The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Blood. 1997;89(5):1471–82. doi:10.1182/blood.V89.5.1471.
   PubMedGoogle Scholar
• Munoz L, Nomdedeu JF, Lopez O, Carnicer MJ, Bellido M, Aventín A, Brunet S, Sierra J. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261–69.
   PubMed Web of Science ®Google Scholar
• Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019;104(4):749–55. doi:10.3324/haematol.2018.205252.
   PubMed Web of Science ®Google Scholar
• Djokic M, Bjorklund E, Blennow E, Mazur J, Soderhall S, Porwit A. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica. 2009;94(7):1016–19. doi:10.3324/haematol.2008.000299.
   PubMed Web of Science ®Google Scholar
• Lhermitte L, de Labarthe A, Dupret C, Lapillonne H, Millien C, Landman-Parker J, Hermine O, Baruchel A, Sigaux F, Macintyre E. Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy. Leukemia. 2006;20(10):1908–10. doi:10.1038/sj.leu.2404349.
   PubMed Web of Science ®Google Scholar
• Du W, Li J, Liu W, He Y, Yao J, Liu Y, Lin J, Zheng J. Interleukin-3 receptor alpha chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy. Tumour Biol. 2016;37(3):3817–21. doi:10.1007/s13277-015-3272-y.
   PubMedGoogle Scholar
• Del Giudice I, Matutes E, Morilla R, Morilla A, Owusu-Ankomah K, Rafiq F, A’Hern R, Delgado J, Bazerbashi MB, Catovsky D. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica. 2004;89:303–08.
   PubMed Web of Science ®Google Scholar
• Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadié M. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624–36. doi:10.1111/j.1365-2141.2009.07679.x.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Reichard KK, Zblewski D, Abdelrahman RA, Wassie EA, Morice II WG, Brooks C, Grogg KL, Hanson CA, Tefferi A. CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value. Leukemia. 2016;30(4):914–18. doi:10.1038/leu.2015.348.
   PubMed Web of Science ®Google Scholar
• Fromm JR. Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma. Cytometry B Clin Cytom. 2011;80(2):91–99. doi:10.1002/cyto.b.20561.
   PubMedGoogle Scholar
• Testa U, Riccioni R, Diverio D, Rossini A, Lo Coco F, Peschle C. Interleukin-3 receptor in acute leukemia. Leukemia. 2004;18(2):219–26. doi:10.1038/sj.leu.2403224.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–84. doi:10.1038/sj.leu.2401903.
   PubMed Web of Science ®Google Scholar
• Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126(10):3814–26. doi:10.1172/JCI87366.
   PubMed Web of Science ®Google Scholar
• Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5(1):31–42. doi:10.1016/j.stem.2009.04.018.
   PubMed Web of Science ®Google Scholar
• Testa U, Riccioni R, Militi S. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980–88.
   PubMed Web of Science ®Google Scholar
• Vergez F, Green AS, Tamburini J, Sarry J-E, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96(12):1792–98. doi:10.3324/haematol.2011.047894.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O’Donnell M, Stein AS, Marcucci G, Forman S, Pullarkat V. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92(9):858–65. doi:10.1002/ajh.24783.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014;28(11):2213–21. doi:10.1038/leu.2014.128.
   PubMed Web of Science ®Google Scholar
• Cuesta-Mateos C, Alcaraz-Serna A, Somovilla-Crespo B, Munoz-Calleja C. Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets. Front Immunol. 2017;8:1936.
   PubMed Web of Science ®Google Scholar
• Kubasch AS, Schulze F, Giagounidis A. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2019;34:1182–1186.
   Web of Science ®Google Scholar
• Montesinos P, Roboz GJ, Bulabois C-E. 2020. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia. doi:10.1038/s41375-020-0773-5
   Google Scholar
• Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 2000;13(8):575–81. doi:10.1093/protein/13.8.575.
   PubMedGoogle Scholar
• Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–37. doi:10.1056/NEJMoa1815105.
   PubMed Web of Science ®Google Scholar
• Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, Wang R, Przepiorka D, Shen YL, Leong R. FDA approval summary: tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2020;26(3):532–36. doi:10.1158/1078-0432.CCR-19-2329.
   PubMed Web of Science ®Google Scholar
• Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019;129(11):5005–19. doi:10.1172/JCI128571.
   PubMed Web of Science ®Google Scholar
• Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49(3):543–53. doi:10.1080/10428190701799035.
   PubMed Web of Science ®Google Scholar
• Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K. Characterization of SGN-CD123A, A potent CD123-directed antibody-drug conjugate for acute myeloid leukemia. Mol Cancer Ther. 2018;17(2):554–64. doi:10.1158/1535-7163.MCT-17-0742.
   PubMed Web of Science ®Google Scholar
• Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, Bai C, Rui L, Laleau R, Liu F. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848–58. doi:10.1182/bloodadvances.2018017517.
   PubMed Web of Science ®Google Scholar
• Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Deconinck E, Erba HP, Pemmaraju N, Lane AA, Rizzieri DA. Clinical profile of IMGN632, a novel CD123-targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood. 2019;134(Supplement_1):734–734. doi:10.1182/blood-2019-128648.
   Web of Science ®Google Scholar
• Daver NG, Erba HP, Papadantonakis N, DeAngelo DJ, Wang ES, Konopleva MY, Sloss CM, Wang J, Malcolm KE, Zweidler-McKay PA. A phase 1b/2 study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia. Blood. 2019;134(Supplement_1):2601–2601. doi:10.1182/blood-2019-128501.
   Google Scholar
• Chichili GR, Huang L, Li H. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015;7(289):289ra282. doi:10.1126/scitranslmed.aaa5693.
   Web of Science ®Google Scholar
• Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016;127(1):122–31. doi:10.1182/blood-2014-05-575704.
   PubMed Web of Science ®Google Scholar
• Uy GL, Aldoss I, Foster MC, Sallman DA, Sweet KL, Rizzieri DA, Sayre PH, Advani AS, Emadi A, Wieduwilt MJ. Flotetuzumab, an Investigational CD123 x CD3 bispecific dart® protein, in salvage therapy for primary refractory and early relapsed Acute Myeloid Leukemia (AML) patients. Blood. 2019;134(Supplement_1):733–733. doi:10.1182/blood-2019-122073.
   Google Scholar
• Bakkacha O, Uy GL, Aldoss I, Foster MC, Sallman DA, Sweet KL, Rizzieri DA, Sayre PH, Advani AS, Emadi A. Improvement in cytokine release syndrome management for the treatment of AML patients with flotetuzumab, a CD123 x CD3 bispecific dart® molecule for t-cell redirected therapy. Blood. 2019;134(Supplement_1):5144–5144. doi:10.1182/blood-2019-127138.
   Web of Science ®Google Scholar
• Kenderian SS, Ruella M, Shestova O, Kim M, Klichinsky M, Chen F, Kengle N, Lacey S, Melenhorst J, June CH. 2 - ruxolitinib prevents cytokine release syndrome after car T-cell therapy without impairing the anti-tumor effect in a xenograft model. Biol Blood Marrow Transplant. 2017;23(3,Supplement):S19–S20. doi:10.1016/j.bbmt.2016.12.003.
   Web of Science ®Google Scholar
• Rettig MP, Godwin J, Vey N. Preliminary translational results from an ongoing phase 1 study of flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: rationale for combining flotetuzumab and anti-PD-1/PD-L1 immunotherapies. Blood. 2017;130:1365–1365.
   Web of Science ®Google Scholar
• Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan AH, Viboch EJ, Patel T, Ibrahimova N. Immune landscapes predict chemotherapy resistance and anti-leukemic activity of flotetuzumab, an investigational CD123×CD3 bispecific dart® molecule, in patients with relapsed/refractory acute myeloid leukemia. Blood. 2019;134(Supplement_1):460–460. doi:10.1182/blood-2019-121870.
   Google Scholar
• Ravandi F, Bashey A, Foran JM, Stock W, Mawad R, Blum W, Saville MW, Johnson CM, Vanasse KGJ, Ly T. Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody: initial results of a phase 1 study. Blood. 2018;132(Supplement 1):763–763. doi:10.1182/blood-2018-99-119786.
   Google Scholar
• Gaudet F, Nemeth JF, McDaid R, Li Y, Harman B, Millar H, Teplyakov A, Wheeler J, Luo J, Tam S. Development of a CD123xCD3 bispecific antibody (JNJ-63709178) for the treatment of acute myeloid leukemia (AML). Blood. 2016;128(22):2824–2824. doi:10.1182/blood.V128.22.2824.2824.
   PubMed Web of Science ®Google Scholar
• Hernandez-Hoyos G, Sewell T, Bader R, Bannink J, Chenault RA, Daugherty M, Dasovich M, Fang H, Gottschalk R, Kumer J. MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther. 2016;15(9):2155–65. doi:10.1158/1535-7163.MCT-15-0242.
   PubMed Web of Science ®Google Scholar
• Comeau MR, Miller RE, Bader R. Abstract 1786: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release. Cancer Res. 2018;78:1786–1786.
   Web of Science ®Google Scholar
• Park JH, Riviere I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59. doi:10.1056/NEJMoa1709919.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28. doi:10.1016/S0140-6736(14)61403-3.
   PubMed Web of Science ®Google Scholar
• Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343–54. doi:10.1182/blood-2013-09-529537.
   PubMed Web of Science ®Google Scholar
• Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T. Redirecting specificity of T cells using the sleeping beauty system to express chimeric antigen receptors by mix-and-matching of VL and VH domains targeting CD123+ tumors. PLoS One. 2016;11(8):e0159477. doi:10.1371/journal.pone.0159477.
   PubMed Web of Science ®Google Scholar
• Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GMP, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161(3):389–401. doi:10.1111/bjh.12282.
   PubMed Web of Science ®Google Scholar
• Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang W-C, Bretzlaff W. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18):3138–48. doi:10.1182/blood-2012-12-474056.
   PubMed Web of Science ®Google Scholar
• Budde L, Song JY, Kim Y. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: A first-in-human clinical trial. Blood. 2017;130:811–811.
   Web of Science ®Google Scholar
• Yao S, Jianlin C, Yarong L, Botao L, Qinghan W, Hongliang F, Lu Z, Hongmei N, Pin W, Hu C. Donor-derived CD123-targeted CAR T Cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML. Front Oncol. 2019;9:1358. doi:10.3389/fonc.2019.01358.
   PubMed Web of Science ®Google Scholar
• Tu S, Deng L, Huang R, Zhou X, Yang J, Zhou W, Li M, Yue C, Wu S, Guo Z. A novel chimeric antigen receptor T cells therapy strategy that dual targeting CD19 and CD123 to treat relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Blood. 2018;132(Supplement 1):4015–4015. doi:10.1182/blood-2018-99-118526.
   Web of Science ®Google Scholar